{"nctId":"NCT02694978","briefTitle":"A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)","startDateStruct":{"date":"2016-02-29","type":"ACTUAL"},"conditions":["Iron Deficiency Anemia"],"count":2014,"armGroups":[{"label":"Ferumoxytol","type":"EXPERIMENTAL","interventionNames":["Drug: Ferumoxytol"]},{"label":"FCM","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: FCM"]}],"interventions":[{"name":"Ferumoxytol","otherNames":["Feraheme"]},{"name":"FCM","otherNames":["Injectafer, Ferinject"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria include:\n\n* Participants with IDA and in whom IV iron treatment is indicated and defined as:\n\n  * Participants with documented hemoglobin \\<12.0 g per deciliter (dL) for females and \\<14.0 g/dL for males within 60 days of dosing And\n  * Participants with documented transferrin saturation (TSAT) ≤20% or Ferritin ≤100 nanograms (ng) per mL within 60 days of dosing\n* Documented history of unsatisfactory oral iron therapy or in whom oral iron cannot be tolerated, or for whom oral iron is considered medically inappropriate (as per oral iron history questionnaire)\n* All participants (male and female) of childbearing potential who are sexually active who agree to routinely use adequate contraception from randomization throughout the duration of the study\n\nKey Exclusion Criteria include:\n\n* Known hypersensitivity reaction to any component of ferumoxytol or FCM\n* History of allergy to an IV iron\n* History of multiple drug allergies\n* Participants with dialysis-dependent chronic kidney disease\n* Hemoglobin ≤7.0 g/dL\n* Female participants who are pregnant, intend to become pregnant, are breastfeeding, have a positive serum/urine pregnancy test or not willing to use effective contraceptive precautions during the study (including females of childbearing potential who are partners of male participants)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension","description":"All IV iron formulations carry some risk of serious hypersensitivity reactions or anaphylaxis. Signs and symptoms potentially representing hypersensitivity were recorded and adjudicated by a blinded Clinical Events Committee (CEC). Hypotension is defined as a \\>30% drop in systolic blood pressure from baseline or decrease of \\>20 mmHg for systolic blood pressure.\n\nStatistical analysis was only performed on composite data. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With Moderate To Severe Hypersensitivity Reactions, Including Anaphylaxis, Serious Cardiovascular Events, And Death","description":"All IV iron formulations carry some risk of serious hypersensitivity reactions or anaphylaxis. Signs and symptoms potentially representing hypersensitivity were recorded and adjudicated by a blinded Clinical Events Committee (CEC).\n\nA summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change In Hemoglobin From Baseline To Week 5","description":"Mean change in hemoglobin from Baseline to Week 5 was calculated for each participant as: Hemoglobin Change = Hemoglobin (Week 5) - Hemoglobin (Baseline). Baseline was defined as the Day 1 value (prior to injection of study drug). The screening or most recent value prior to Day 1 was used for any participant with missing Day 1 information.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":"1.351"},{"groupId":"OG001","value":"1.63","spread":"1.535"}]}]}]},{"type":"SECONDARY","title":"Mean Change In Hemoglobin Per Gram Of Iron Administered From Baseline To Week 5","description":"Mean change in hemoglobin per g of iron administered from Baseline (Day 1) to Week 5 was calculated for each participant as: Hemoglobin Change = Hemoglobin (Week 5) - Hemoglobin (Baseline). Baseline was defined as the Day 1 value (prior to injection of study drug). The screening or most recent value prior to Day 1 was used for any participant with missing Day 1 information.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.35","spread":"1.353"},{"groupId":"OG001","value":"1.10","spread":"1.050"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":997},"commonTop":["Headache","Nausea","Fatigue","Dizziness","Diarrhoea"]}}}